Objective: Charcot-Marie-Tooth disease (CMT) is a common heritable peripheral neuropathy. There is no treatment for any form of CMT, although clinical trials are increasingly occurring. Patients usually develop symptoms during the first 2 decades of life, but there are no established outcome measures of disease severity or response to treatment. We identified a set of items that represent a range of impairment levels and conducted a series of validation studies to build a patient-centered multi-item rating scale of disability for children with CMT. Methods: As part of the Inherited Neuropathies Consortium, patients aged 3 to 20 years with a variety of CMT types were recruited from the USA, United Kingdom, Italy, and Australia. Initial development stages involved definition of the construct, item pool generation, peer review, and pilot testing. Based on data from 172 patients, a series of validation studies were conducted, including item and factor analysis, reliability testing, Rasch modeling, and sensitivity analysis. Results: Seven areas for measurement were identified (strength, dexterity, sensation, gait, balance, power, endurance), and a psychometrically robust 11-item scale was constructed (CMT Pediatric Scale [CMTPedS]). Rasch analysis supported the viability of the CMTPedS as a unidimensional measure of disability in children with CMT. It showed good overall model fit, no evidence of misfitting items, and no person misfit, and it was well targeted for children with CMT. Interpretation: The CMTPedS is a well-tolerated outcome measure that can be completed in 25 minutes. It is a reliable, valid, and sensitive global measure of disability for children with CMT from the age of 3 years. ANN NEUROL 2012;71:642-652 C harcot-Marie-Tooth disease (CMT) is named for the 3 neurologists who described it in the late 1800s.
axons in the peripheral nervous system. These mutations have illuminated important intracellular pathways leading to demyelination or axonal degeneration, including intracellular protein trafficking, axonal transport, regulation of transcription, and mitochondrial fusion/fission. As a result, rational hypothesis-driven treatment approaches are underway, and some clinical trials for CMT1A, the most common form of CMT, have been completed. [4] [5] [6] [7] However, clinical trials depend on carefully chosen outcome measures used in appropriately selected patients to have the best chance of success.
Outcome measures need to be clinimetrically well validated and meet the demands of being well tolerated, valid, reliable, and sensitive. 8 In adults with CMT, the CMT Neuropathy Score (CMTNS) has been implemented as the primary outcome measure in numerous drug trials. 5, 6 The CMTNS is a composite score based on patient history, neurological examination, activity limitations, and clinical neurophysiology, and can detect an increase in impairment on a yearly basis. 9 However, the CMTNS has limited sensitivity in children to differentiate levels of disease severity, 10 and the influence of growth and development that normally occurs during childhood on the CMTNS is unknown. Because most forms of CMT affect children, there is a need for a clinical tool to measure impairment in children with CMT. For example, most patients with CMT1A 11 and CMT1X, 12,13 the 2 most common forms of CMT, develop symptoms within the first 2 decades of life. Many patients with CMT2A, the most common form of CMT2, are wheelchair bound by 21 years of age. 14 Moreover, childhood may be the ideal time to institute treatments for CMT, before chronic changes of demyelination or axonal degeneration have occurred that make repair more difficult. 15 In this article, we describe efforts by our Inherited Neuropathies Consortium to develop a multidimensional pediatric scale for children with CMT. The first crucial step in designing such a scale was to ensure its ability to measure outcomes that are relevant to neuropathy and disability, using test items that are sufficiently sensitive and responsive to change. This allows precise assessment of baseline performance and disease severity, monitoring of outcomes longitudinally in studies of natural history, and determination of responses to existing and novel interventions. Our scale needed to be unambiguously constructed to represent only 1 of the outcome levels according to the International Classification of Functioning, Disability, and Health (ICF). 16 Disability has been proposed as the preferential level for measuring therapeutic response in adults and children with CMT. 8 The World Health Organization (WHO) defines disability as an umbrella term, covering impairments, activity limitations, and participation restrictions. Most disability scales used in the neuropathies have been validated using Classical Test Theory statistical techniques, such as inter-item correlations and factor analysis. Use of new psychometric methods such as the Rasch model, a modern technique that forms part of Item Response Theory, is regarded as a more clinically and scientifically meaningful scale development approach to measure disability. 17 Rasch analysis is a probabilistic mathematical modeling technique used to assess properties of outcome measures including unidimensionality (extent to which items measure a single construct), item difficulty (relative difficulty of the items when compared to each other), and person separation (extent to which items distinguish between distinct levels of functioning). Rasch analysis has been widely used in the development and validation of outcome measures in neurology. 18, 19 In this study, we identified a set of items that represent a range of impairment levels in childhood CMT and conducted a series of validation studies, including Rasch analysis, to build a linearly weighted disability scale for children with CMT, known as the CMT Disease Pediatric Scale (CMTPedS).
Patients and Methods
We conducted 2 phases of research: development and validation of the CMTPedS. Ethics approval from all institutions for all studies and written informed assent/consent from all children and their families were obtained.
The development stages of CMTPedS involved:
Definition of the Construct
An extensive review of the literature on measurement of disability in children with CMT identified the need for a patient-centered multiple-item rating scale with broad application to reflect all aspects of disability in children with all types of CMT from the age of 3 years.
Generation of the Item Pool
We searched Medline (from January 1966), Embase (from January 1980), CINAHL (from January 1982), AMED (from January 1985), Cochrane Neuromuscular Disease Group Specialized Register, and reference lists of articles. We contacted experts in the field to identify additional test items. A large pool of items was generated capturing symptoms, foot and ankle involvement, hand dexterity, strength, sensation, balance, gait, and motor function. The item pool included many tests all tapping the same underlying construct, and were selected based on disease specificity, functional/patient relevance, reliability/validity, responsiveness to change, availability of published norms, duration, and ease of interpretation. Items were reduced based on being simple, safe to administer, well tolerated, valid, reliable, and sensitive.
Peer Review
Quality, suitability, and coverage of potential items was peer reviewed by 23 expert clinicians, scientists, and patient representatives from Australia, Belgium, France, Germany, Italy, Netherlands, Spain, the United Kingdom, and the USA at the 168th European NeuroMuscular Centre International Workshop. 8 Based on experts' opinion, items with insufficient face/ content validity were removed to form the preliminary version of the CMTPedS, containing 37 items.
Pilot Testing
Following training of clinicians from the USA, United Kingdom, Italy, and Australia through a face-to-face workshop, online manual, and video resources, the CMTPedS was pilot tested with 4 affected children to check for administration problems, item instructions, order, and duration. The preliminary CMTPedS could be completed in 45 to 60 minutes and was well accepted by the children. Feedback informed the working version of the CMTPedS, containing 28 items (Table 1) . During a 14-month test period, the working version of the CMTPedS was prospectively administered to 172 children aged 3 to 20 years through the Inherited Neuropathies Consortium. A series of internal and external validation studies were conducted with these data in SPSS v18.0 and RUMM2030, as detailed in 
Item Analysis
With regard to redundancies, all left and right limb paired items (foot posture index, ankle flexibility, functional dexterity test, 9-hole peg test) were highly correlated (r > 0.76-0.90, p < 0.0001), so to avoid a unit of analysis error, 27 we retained 1 limb only (dominant) per item. Hand strength items (grip, thumb-index pinch, 3-point pinch) were highly intercorrelated (r ¼ 0.81-0.92, p < 0.0001), so only grip strength was retained, because 8 children could not produce a thumb-index pinch or 3-point pinch due to their inability to approximate the thumb to the digits because of poor thumb mobility or finger contracture (floor effect). Foot strength items (plantarflexion, dorsiflexion, inversion, eversion) were highly intercorrelated (r ¼ 0.71-0.86, p < 0.0001), except plantarflexion and dorsiflexion (r ¼ 0.65), so only these were retained. Of the function items (balance, long jump, 10m run/walk, stair ascend/descend, 6-minute walk test), there were high correlations (r > 0.76-0.90, p < 0.0001) between the 10m run/walk and stair items. Because these items already correlate substantially with balance, long jump, and 6-minute walk test, and were unlikely to detect differences between children with CMT as most cases were graded as normal (72-82%), only balance, long jump, and 6-minute walk test were retained.
With regard to uncorrelated items, the self-reported symptoms item did not correlate substantially (r > 0.3) with any other item and was retained only for patient profiling purposes.
Scoring
To rate performance across age and gender with the remaining 13 items measured in different units (degrees, seconds, newtons, meters), items were converted to z scores based on age/gender-matched normative reference values collected by the Inherited Neuropathies Consortium and cross-checked with published data [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] and (G. Gogola, Functional Dexterity Test Norms, unpublished). z Scores provided a dimensionless rating approach to the challenge of growth and development, offset by deterioration of strength and function, in children with CMT. See Supplementary Table 2 for the z score conversion process.
To improve interpretation and generate a total score, z scores were categorized along a continuum of disability levels: normal, very mild, mild, moderate, and severe. Our approach, outlined in Supplementary Table 2, mirrors the validated adult CMTNS, which was originally modified from the Total Neuropathy Score 47 by collapsing to a 5-point Likert response format. 48 However, the CMTPedS categories are based on age/gender-derived z scores. This approach provides ease of interpretation and clinical utility by dovetailing with the adult CMTNS. Item analysis of the 13 categorized items showed scores ranging from a low of 0 (normal) to a high of 4 (severe). Mean scores ranged from a low of 0.6 (vibration) to 3.2 (dorsiflexion strength), with all items varying across the full range from 0 to 4. In the inter-item and item total correlation matrix, no pair was very highly correlated (r > 0.7), and all items correlated substantially (r > 0.3) with at least 1 other item. Average interitem correlation was 0.22 (range, À0.09 to 0.54). The itemtotal correlation ranged from 0.14 (ankle flexibility) to 0.67 (6-minute walk test).
Factor Analysis
The 13 items were subjected to principal components analysis (PCA). The Kaiser-Meyer-Olkin value 22 and the Bartlett's Test of Sphericity 23 supported the factorability of the correlation matrix. PCA revealed the presence of 4 components with eigenvalues >1, explaining 32%, 11%, 9%, and 8% of the variance, respectively, for a total of 60%. An inspection of the scree plot revealed a clear break after the second component, supporting the retention of 2 components for further investigation. 24 This was further supported by the results of parallel analysis, which showed 2 components with eigenvalues exceeding the corresponding criterion values for a randomly generated data matrix of the same size (13 items Â 172 cases). The 2-component solution explained a total of 43% of the variance, with component 1 contributing 32% and component 2 contributing 11%. To aid in the interpretation of these 2 components, oblimin rotation was performed. 21 The rotated solution revealed the presence of a simple structure, with both components showing a number of strong loadings and all but 2 items (foot posture index, ankle flexibility), loading substantially on only 1 component. The interpretation of the 2 components suggested that the 11 items on component 1 represent function (strength, dexterity, sensation, balance, gait, power, endurance), whereas the 2 items on component 2 represented structure (deformity, contracture). There was a weak correlation between the 2 factors (r ¼ 0.04). The 20 Uncorrelated items (r < 0.3) were also removed, because low item intercorrelations undermine internal consistency of a measurement scale.
Item scoring
For generalizability, a total score was constructed with items that were converted to a dimensionless variable, z score, and then categorized to a 0-4 Likert scale. A z score indicates how many standard deviations an item is above or below the mean. z scores are a dimensionless quantity derived by subtracting the population mean from an individual raw score and then dividing the difference by the population standard deviation. The advantage of using a z score is that it transforms raw data into a relative expression of distance of that data point from the mean, based upon age-and gender-matched normative data. In this way, a small improvement in the raw data over 2 time points can actually turn out to be a relative decline when compared to changes in age/gender-matched norms. Conversion of raw scores to z scores was based on age/gender-matched normative reference values collected by the Inherited Neuropathies Consortium and cross-checked with extensive published data [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] and (G. Gogola, Functional Dexterity Test Norms, unpublished).
Factor analysis
The CMTPedS was subjected to principal components analysis using SPSS version 18.0 in accordance with an established protocol. 21 4. Reliability For the CMTPedS to be a useful research or clinical tool, it must be reliable. The higher the reliability, the smaller the error. Both internal consistency and test reproducibility were assessed. Internal consistency is the homogeneity of items that make up the scale, that is, the degree to which items hang together, and was calculated with Cronbach coefficient alpha. For reproducibility, an intraclass correlation coefficient (ICC 2,4 ) was calculated using the 2-way random effects model with absolute agreement, single-measures option.
Rasch analysis
In RUMM2030 software, all aspects of the CMTPedS, including the response format, fit of the items, item bias, unidimensionality, and spread of items across the construct being measured, were subjected to Rasch analysis following the procedures recommended by Pallant and Tennant. 20 6. Sensitivity The ability of the CMTPedS to differentiate age, gender, CMT type, neurophysiological features, severity of the disease, and physical characteristics between children was performed using SPSS version 18.0.
Implementation
Worldwide access to CMTPedS resources, equipment, training, computerized scale administration, and online customized scoring software was developed.
results of this analysis supported the use of the function items in accordance with the WHO ICF framework, whereas the structure items were retained only for patient profiling and clinical symmetry. The final 11-item solution explained a total of 49.4% of the variance.
Reliability
Internal consistency, or the degree to which the 11 items group together, was very good, with a Cronbach coefficient alpha value of 0.82. 26 With regard to reproducibility, we conducted an inter-rater reliability study involving 8 affected children (7 girls The item map showed a good spread across the full range of scores for this sample, with no gaps where there were insufficient items to assess specific levels of the trait (Supplementary Fig 1) . Gait was the easiest item to score highly (ie, commonly severely affected), and vibration was the hardest item to score highly (ie, rarely severely affected). There was no clustering at the low or high ends of the distribution (floor or ceiling effects). The final version of the CMTPedS shown in Figure 1 appeared well targeted for use with this group of patients.
Sensitivity
The 11-item CMTPedS score has a possible range of 0 to 44, and scores were normally distributed (Kolmogorov-Smirnov, 0.068; p ¼ 0.2). Of the 172 cases, the mean was 19 (SD, 8) , with a range of 4 to 41 points. Sensitivity analysis identified no difference in mean CMTPedS score between boys (19; SD, 8) and girls (20; SD, 8; t ¼ À0.792, p ¼ 0.430), although as expected there were gender differences for the 11 X-linked cases (boys, 19; SD, 9; girls, 14; SD, 8).
Older age was significantly associated with a higher CMTPedS total score (r ¼ 0.44, p < 0.001), reflecting the progression of the disease with age. Figure 2 suggests a 16-point change from 3 to 20 years. Individual items did not correlate as highly with age (r ¼ 0.15-0.38). Dividing the sample into early childhood (3-8 years), middle childhood (9-14 years), and adolescence (15-20 years), as previously described, 49 showed that the CMTPedS score was significantly higher as the disease progressed through early childhood (mean, 14; SD, 7), middle childhood (mean, 20; SD, 8), and adolescence (mean, 25; SD, 8; F ¼ 16.285, p < 0.0001). With regard to CMT type, children with CMT1A (mean, 17; SD, 7) scored significantly better than those with other types of CMT (mean, 22; SD, 9; t ¼ À3.161, p ¼ 0.002). Moreover, the demyelinating cases, confirmed with clinical neurophysiology, generally scored better (mean, 19; SD, 8) than axonal (mean, 24; SD, 9) cases. Longitudinal data from 15 patients were analyzed to determine whether CMTPedS scores were sensitive to change over a 1-year period, although we recognize that larger numbers of patients will be required to address this issue definitively. Their ages ranged from 4 to 17 years and included 11 patients with CMT1A, 1 each with CMT2A and CMT4A and 2 with unidentified genetic causes. Taken as an aggregate, their scores demonstrated an increase (worsening) of the CMTPedS score from baseline (mean, 20; SD, 10) to 1-year follow-up (mean, 21; SD, 11; Table 3 ). However, scores from the 2 patients with CMT2A and CMT4A, more severe forms of CMT, progressed more than those from most patients with CMT1A, and 1 outlier with more severe CMT1A was identified by an increase of 6 points over a 1-year period (see Table 3 ).
A higher number of self-reported symptoms was modestly associated with higher CMTPedS score (r ¼ 0.24, p ¼ 0.01). In particular the presence of hand 
Implementation
A CMTPedS equipment and item instruction kit, available in Supplementary File 1, was compiled to facilitate worldwide training and implementation. Specialized scoring software was developed to automate the z score conversion and categorization process and batch cases for total scoring based on age/gender-matched normative reference values (Supplementary Fig 2) . This Windows software is available as a free Internet download (http:// cmtpeds.org/).
Discussion
Rating scales, based on modern psychometric validation, are increasingly used as primary outcome measures in natural history studies and clinical trials. The quality of the rating scale has the potential to influence the outcome of clinical trials and patient care. 17 We performed a rigorous development and validation process to evaluate the CMTPedS. Based on the developmental phase of research, the CMTPedS is clinically meaningful, related to an explicit construct, and easily interpretable. Based on the validation phase, the CMTPedS is a stable, reliable, and psychometrically robust outcome measure for young children and adolescents with CMT, enabling precise disease-relevant assessment. Based on the sensitivity analysis, the CMTPedS is highly sensitive to age and CMT type, generally not influenced by gender, and clearly reflects the severity of the disease. There are no other measurement scales for children with CMT. The CMTNS, which has been validated in adults, 48 has limited application in children because only 4 of 9 items are regarded as sensitive. 10 There are few scales in the neuropathy field, 18, 50 and none in the FIGURE 2: Relation between the Charcot-Marie-Tooth Disease Pediatric Scale (CMTPedS) score and advancing age. Older age was significantly associated with a higher CMTPedS score, reflecting the progression of the disease with age.
inherited neuropathies, validated with modern psychometric methods. Rasch has become the preferential method of validation. The Rasch model focuses on the probability of individuals scoring on an item correctly given their responses to other items in the scale (fit). Within the framework of Rasch, the scale should work the same way, irrespective of the group being assessed (eg, items should behave similarly independent of age, gender, or diagnosis grouping). 20 Rasch analysis supported the viability of the 11-item CMTPedS as a unidimensional measure of disability in children with CMT. It showed good overall model fit, no evidence of misfitting items, no person misfit, ability to differentiate groups of patients, and no differential item functioning, and it was well targeted for children with CMT. There is international support for the CMTPedS to be implemented as the primary outcome measure in studies of children with CMT. 8 The CMTPedS was designed to supplement a thorough neurological examination and capture functionally relevant limitations caused by CMT in the pediatric population. It is intended to have broad application in natural history studies and clinical trials of rehabilitative (eg, orthoses, stretching, strengthening), pharmacological (eg, curcumin, antiprogesterone), and surgical (eg, foot and hand tendon transfer, arthrodesis, hip dysplasia) interventions. At this stage, and by design, the CMTPedS is limited to children. However, because it is based on activities that are relevant to daily life, there will be a demand to broaden the application of the CMTPedS to enable longterm studies into adulthood to ensure consistent measurement across the lifespan of patients with CMT. This study is primarily based on a cross-sectional analysis. In the future, 5-year follow-up data will be available through the Inherited Neuropathies Consortium to determine the longitudinal responsiveness and minimal clinically important difference of the CMTPedS. These data will demonstrate how large a change in CMTPedS points would be regarded by patients, parents, and clinicians as indicating a meaningful improvement in day-to-day function following an experimental intervention. Different subtypes of CMT vary in severity and rate of progression. For instance, CMT1A, the most common form of CMT, is thought to progress quite slowly during childhood, whereas patients with CMT2A are wheelchair bound by 21 years of age. Therefore, as suggested by our preliminary longitudinal data, it is likely that the rate of change of CMTPedS will vary, depending on the CMT subtype. To determine this experimentally will undoubtedly require larger numbers of children with different subtypes assessed longitudinally for 2 to 5 years, as we propose to do within our consortium. Furthermore, even within subtype, patient-topatient variability will influence the rate of change of the CMTPedS. For instance, the preliminary longitudinal data revealed 5 cases of CMT1A that showed an improvement on the CMTPedS, whereas the other 6 cases of CMT1A did not. This accurately reflects the well-known heterogeneity of the disease, particular during childhood, where rapid periods of growth and development can produce a variable clinical presentation and rate of progression. Indeed, results from our 1-year placebo-controlled clinical trial of ascorbic acid for 81 children with CMT1A showed some cases of marked improvement in strength and motor function equally in both the treatment and control groups. 4 Although the CMTPedS was not utilized in this trial as an outcome measure, the fundamental components of strength and motor function are common elements and illustrate the point of variability in patient response during childhood growth and development. The implications of this phenotypic variability on future clinical trial design require larger samples to increase power and longer follow-up duration to account for natural growth fluctuations.
In conclusion, the final 11-item CMTPedS is a well-tolerated outcome measure that can be completed in 25 minutes. It generates a normally distributed score ranging from 0 to 44 points that is a reliable, valid, and sensitive measure of disability for children with CMT from the age of 3 years.
